Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EPS (Weighted Average and Diluted) (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.2 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 47.37% to -$0.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.29 through Dec 2025, up 23.67% year-over-year, with the annual reading at -$1.29 for FY2025, 23.21% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.2 in Q4 2025 for Prelude Therapeutics, up from -$0.26 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.2 in Q4 2025 to a low of -$0.46 in Q2 2024.